The Transfer of All Commercial Rights for Panaldine
TOKYO, April 2, 2007 — DAIICHI SANKYO
COMPANY, LIMITED and Sanofi-aventis announced today the transfer of
all commercial rights for Panaldine (ticlopidine hydrochloride ) in
Japan from DAIICHI SANKYO to Sanofi-aventis. The transfer will be
implemented in conformity with local regulatory requirements and
such transfer is expected to occur on October 1, 2007. Given their
long-standing relationship, both parties agreed to collaborate in
the future in the areas of manufacturing and distribution in
Japan.
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.co.jp/
Posted: April 2007
